B2BROKER
28.1.2020 11:15:06 CET | Business Wire | Press release
B2Broker, a leading liquidity and technology provider of solutions to the Forex and crypto industry, has signed an agreement with Devexperts , a financial software developer, to license their dxTrade platform. dxTrade is a multi-asset trading solution for brokers which, unlike other existing OTC trading platforms, supports the entire spectrum of assets. This feature will allow B2Broker to become the leading Prime of Prime liquidity provider in the industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200128005354/en/
B2Broker’s pool of trading platforms currently includes OneZero Hub, PrimeXM xCore, several MT4 and MT5 trading platforms, together with B2Trader (the company’s own Matching Engine platform). With the addition of dxTrade, clients will be able to gain quick and easy access to one of the deepest liquidity pools in the industry for Stocks/Equities, ETFs, CFDs, Futures, Vanilla Options, Commodities, Metals, Forex, Crypto Futures, Crypto Spot, Crypto CFD and Bonds.
The company, which recently expanded its Crypto CFD liquidity offering with the addition of 61 new crypto pairs, now totalling 100 pairs, is recognised as being one of the industry’s leading LPs, offering the highest level of support with 24/7 trading and support in English, Russian, Chinese Cantonese and Simplified, Arabic, Spanish, Hindu, Italian, Urdu, Farsi, Pashto, Hebrew and Turkish.
B2Broker recently completed its integration with the dxTrade platform in order to spread liquidity amongst brokers who already use dxTrade, and to offer it to newly established or expanding brokers. From now on, they will be able to connect to one of the largest liquidity pools in the industry in just one minute through FIX API or by connecting to dxTrade directly.
Moreover, B2Broker has integrated B2Core with dxTrade. B2Core, the new name for Trader’s Room , is a ready-made functional solution for brokerages which allows clients to verify and register customers and perform functions such as accepting and sending payments, make deposits and withdrawals and open accounts, etc. Companies who use the dxTrade platform can quickly get connected to B2Core prior to launching their own brokerage business.
Finally, the company’s cryptocurrency payment gateway, B2BinPay , has also been integrated with dxTrade, enabling clients to securely and cost-effectively send, receive, store, exchange and accept cryptocurrency payments online.
Arthur Azizov, Founder and CEO of B2Broker commented, “Our goal to become a global Prime of Prime liquidity provider became a reality thanks to our tailored version of dxTrade which, in combination with our technology and depth of liquidity, makes our offering unmatchable in the industry.”
Evgeny Sorokin, SVP of Software Engineering, Devexperts added: “We are pleased that B2Broker has chosen our modular multi-asset trading platform. dxTrade can be configured to serve different clients in different markets and I am certain that our technology will assist B2Broker with their expansion.”
About B2Broker
B2Broker is a liquidity and technology provider of solutions for the crypto and foreign exchange industry. The company specialises in the sphere of B2B services and products, catering for a wide range of clients including large licensed brokers, crypto exchanges, crypto brokers, forex brokers, hedge and crypto funds and professional managers.
B2Broker’s advanced base of ready to use technical solutions enable brokers to save time and money on consuming infrastructure projects and focus on enlarging their client base and increasing their revenues.
About Devexperts
Devexperts specializes in the development of tailored software solutions for the Capital Markets industry with clients including retail and institutional brokerage houses, exchanges, and wealth management firms. Devexperts are the developers of the thinkorswim platform and numerous recognized and reliable financial applications, with millions of traders using their technology daily. The services from Devexperts include low-latency market data feeds, AR/VR data visualization, AI digital assistants, deep learning, and market analysis.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200128005354/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release
Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month
Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release
Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release
Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release
− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex
Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release
Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom